Stereotactic Body Radiotherapy for Prostate Cancer

M

Mercy Research

Status

Completed

Conditions

Prostate Cancer

Treatments

Radiation: stereotactic body radiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT01352598
11-022

Details and patient eligibility

About

This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.

Full description

This is a single site, non-randomized, prospective, phase IV trial of patients with organ-confined prostate cancer. Data collected will include patient demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received by adjacent critical normal tissues,tumor recurrence data, and acute and late toxicities. Follow up data will be collected during the patient's standard office visits. The anticipated duration of this study is 5 years.

Enrollment

84 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Patient age >= 18 years
  • Zubrod performance status of 0-3
  • T1-3 N0 M0 adenocarcinoma of the prostate
  • Prostate volume ≤ 100 cc
  • Signed study-specific consent form

Exclusion Criteria

  • Extension of local tumor to involve adjacent organs other than seminal vesicles (T4)
  • Prostate volume > 100 cc
  • Nodal involvement
  • Metastatic disease
  • Prior pelvic radiotherapy except as part of combination therapy for prostate cancer
  • History of scleroderma
  • Patients with psychiatric or addictive disorder that would preclude obtaining informed consent

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

84 participants in 1 patient group

Stereotactic Body Radiotherapy
Other group
Description:
Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
Treatment:
Radiation: stereotactic body radiotherapy

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems